DisperSol Technologies

DisperSol Technologies—now operating as AustinPx Pharmaceutics and Manufacturing—is a clinical-stage biotech company specializing in reformulating challenging small molecule drugs using its proprietary KinetiSol® technology. The company’s pipeline includes late-stage assets such as DST–0509 for iron overload disorder entering Phase 3 trials and DST–2970 in Phase 2 for refractory metastatic prostate cancer. Additional candidates target oncology and rare disease indications. The KinetiSol® platform enables the development of therapeutics from poorly bioavailable compounds that are otherwise difficult to formulate or manufacture.